Hospira re-launches oxaliplatin injection in U.S.

By Admin
Share
Hospira Inc said it has re-launched oxaliplatin injection in the U.S. The worlds leading provider of injectible drugs and infusion technologies has lau...

Hospira Inc said it has re-launched oxaliplatin injection in the U.S. The world’s leading provider of injectible drugs and infusion technologies has launched the injection, its generic version of Sanofi’s chemotherapy medication Eloxatin®. The sale of Eloxatin last year in the U.S. was approximately $1.5 billion.  

Joshua Gordon, Vice President, Specialty Pharmaceuticals, said, “We are excited to once again be able to provide this critical oncology drug to our patients and customers.” “Hospira is committed to bringing safe,  lower-cost generic versions of important medications to the market as soon as possible, and in this case we’re able to do so a year ahead of patent expiration for the originator product, which will contribute to much-needed cost savings for our customers," he added.

The oxaliplatin injection is a widely used oncology agent used to help treat colon and colorectal cancer. The company will initially offer the injection in 50 mg and 100 mg single-use vials.  It is a solution form of the product.

This injection was initially launched in August 2009 following a favorable ruling patent litigation with Sanofi.The company settled litigation with Sanofi in 2010 under the agreement which called for the eventual suspension of the sales of Hospira at the end of June 2010, with the right to re-launch the product in advance of the patent expiry, the news reports said.

Hospira Inc is a global market leader for the generic injectable pharmaceuticals. It is uniquely positioned to Advance Wellness by improving patent and caregiver safety while reducing the cost of healthcare.

Share

Featured Articles

NTT & Olympus: World's First Cloud Endoscopy System

NTT and medical technology company Olympus put on a demonstration, showing the IOWN APN's low-latency capability, for the first cloud endoscopy system

Richter BioLogics' New Biopharmaceutical GMP Facility

Richter BioLogics GmbH & Co KG's a new biopharmaceutical GMP facility in Germany will boost production capabilities and local employment

GE HealthCare's Pilot Study Shows Value of Portrait Mobile

A pilot study from GE Healthcare has shown the value of Portrait Mobile Continuous Monitoring Solution, a leap in post-surgical monitoring efficiency

50% of Teens to be Affected by Myopia Globally by 2050

Telehealth & COVID-19

NVIDIA’s AI Insights for Diabetes Prevention with GluFormer

Technology & AI

Novo Nordisk's CagriSema Next Gen Weight-Loss Treatment

Medical Devices & Pharma